N. Roche (Paris, France), A. Ceccato (barcelona, Spain)
Safety and efficacy of apremilast in adults hospitalized with COVID-19
M. Jain (Chicago, United States), M. Bacci (Santo Andre, Brazil), A. Gavrylov (Kharkiv, Ukraine), B. Hochberger (Osorno, Chile), S. Alvarez (Tijuana, Mexico), T. Alvarez (Rosario, Argentina), J. Persichino (Riverside, United States), P. Charuworn (Thousand Oaks, United States), C. Milmont (Thousand Oaks, United States), R. Zhang (Thousand Oaks, United States), R. Elenjical (Centurion, South Africa)
|   |
A phase 3 study to evaluate the efficacy and safety of reparixin in severe COVID-19 pneumonia
G. Landoni (Milan, Italy), A. Voza (Milan, Italy), M. Puoti (Milan, Italy), N. Coppola (Naples, Italy), H. Akselrod (Washington D.C., United States), E. Gavioli (Boston, United States), E. Minnella (Milan, Italy), S. Toya (Milan, Italy), C. Marsiglia (Milan, Italy), F. Sergio (Milan, Italy), M. Allegretti (Milan, Italy), F. Mantelli (Milan, Italy)
| |
Efficacy and safety of garadacimab in patients with severe COVID-19
A. Papi (Ferrara, Italy), R. Stapleton (Burlington, United States), P. Shore (Pennsylvania, United States), M. Bica (Marburg, Germany), Y. Chen (Pennsylvania, United States), M. Larbig (Bern, Switzerland), T. Welte (Hannover, Germany)
| |
Cotrimoxazole in hospitalised patients with severe COVID-19 – interim results from the CoTroxCov study
S. Quadery (Sutton, United Kingdom), T. John (Epsom, United Kingdom), P. Sinha (Kolkata, India), M. Bhattacharjee (Kolkata, India), S. Bose (Kolkata, India), U. Ghosh (Kolkata, India), B. Bhattacharyya (Kolkata, India), S. Tripathi (Kolkata, India), B. Saha (Kolkata, India)
| |
Outcomes of a phase 2 trial for the inhaled JAK inhibitor, nezulcitinib, in hospitalized patients with acute lung injury due to severe COVID-19
R. Saggar (South San Francisco, United States), D. Singh ( Wythenshawe, United Kingdom), E. Moran (South San Francisco, United States), D. Lombardi (South San Francisco, United States), T. Nguyen (South San Francisco, United States), D. Bourdet (South San Francisco, United States), N. Pfeifer (South San Francisco, United States), J. Woo (South San Francisco, United States), J. Belperio (Los Angeles, United States)
| |
Inhaled beclomethasone in the treatment of early COVID-19: a double blind, placebo-controlled trial
C. Ranasinha (Ragama, Sri Lanka), C. Mettananda (Ragama, Sri Lanka), A. Pathmeswaran (Ragama, Sri Lanka), C. Peiris (Ragama, Sri Lanka), A. Gunasekara (Ragama, Sri Lanka), D. Abeyrathna (Ragama, Sri Lanka), T. Egodage (Ragama, Sri Lanka), C. Dantanarayana (Ragama, Sri Lanka)
| |
Value of Montelukast as a potential treatment of Post COVID-19 Persistent cough: A randomized controlled pilot study
A. Mohamed-Hussein (Assiut, Egypt), I. Galal (Aswant, Egypt), M. Ibrahim (Assiut, Egypt), H. Makhlouf (Assiut, Egypt), N. Makhlouf (Assiut, Egypt), H. Abdel Aal (Assiut, Egypt), K. Kholief (Assiut, Egypt)
| |
AM3, a natural glycoconjugate, as adjuvant treatment for COVID-19 patients
D. GÓMEZ-GARRE (Madrid, Spain), A. Ortega-Hernández (Madrid, Spain), J. Modrego (Madrid, Spain), R. Gómez-Gordo (Madrid, Spain), L. Espino (Madrid, Spain), N. Martell (Madrid, Spain), A. Corbatón (Madrid, Spain)
| |
Factors associated with non-invasive positive pressure ventilation failure in a COVID-19 Intermediate Care Unit
I. Farinha (Coimbra, Portugal), A. Cunha (Coimbra, Portugal), F. Costa (Coimbra, Portugal)
| |
Tocilizumab reduces the need for mechanical ventilation in severe Coronavirus Disease 2019 (COVID19); the Greek Experience in a pragmatic clinical setting
G. Hardavella (Athens, Greece), E. Bellou (Athens, Greece), E. Keramida (Athens, Greece), N. Papaioannou (Athens, Greece), I. Bracka (Athens, Greece), S. Mazarakis (Athens, Greece), I. Karampinis (Athens, Greece), N. Anastasiou (Kifissia, Athens, Greece), X. Theiakos (Athens, Greece), P. Demertzis (Athens, Greece)
| |
Effect of colchicine on clinical outcomes in COVID-19
S. Abdenneji (Medenine, Tunisia), W. Fekih (Medenine, Tunisia), I. Ben Krayen (Medenine, Tunisia), J. El Ghoul (Medenine, Tunisia)
| |
Real-life prospective study on tocilizumab in severe COVID-19 infection
L. Power (Dublin, Ireland), B. Morarasu (Dublin, Ireland), A. Sarfaraz (Dublin, Ireland), A. Basirat (Dublin, Ireland), H. Rahman (Dublin, Ireland), S. Donnelly (Dublin, Ireland), E. Moloney (Dublin, Ireland), M. Kooblall (Dublin, Ireland), S. Lane (Dublin, Ireland)
| |
EFFECT OF ANTICOAGULANTS ON THROMBOEMBOLIC EVENTS IN COVID-19 PATIENTS DISCHARGED FROM HOSPITAL AND OUTPATIENTS
C. ÇINAR (istanbul, Turkey), Z. Balaban (istanbul, Turkey), S. Kesim (istanbul, Turkey), F. Sen (istanbul, Turkey), S. Karakurt (istanbul, Turkey), T. Erdil (istanbul, Turkey), T. Önes (istanbul, Turkey), S. Eryüksel (istanbul, Turkey)
| |
No benefit of a prolonged course of corticosteroids in patients with COVID-19 secondary organizing pneumonia
B. Artignan (Nantes, France), S. Dirou (Nantes, France), M. Wargny (Nantes, France), A. Moui (Nantes, France), V. Danielo (Nantes, France), C. Defrance (Nantes, France), R. Liberge (Nantes, France), O. Morla (Nantes, France), M. Chauveau (Nantes, France), P. Le Turnier (Nantes, France), A. Asquier Khati (Nantes, France), A. Espitia Thilbault (Nantes, France), M. Artifoni (Nantes, France), M. Agbakou (Nantes, France), L. Desmedt (Nantes, France), A. Boureau (Nantes, France), E. Eschapasse (Nantes, France), F. Blanc (Nantes, France)
| |
Safety and efficacy of pamrevlumab (FG-3019) in patients with COVID-19 pneumonia: an open-label, randomized, parallel-arm phase 2 study
G. Sgalla (Rome, Italy), J. Simonetti (Rome, Italy), G. Gualano (Rome, Italy), P. Maria Leone (Rome, Italy), A. Comes (Rome, Italy), D. Verdirosi (Rome, Italy), L. Poole (San Francisco, United States), E. Kouchakji (San Francisco, United States), F. Palmieri (Rome, Italy), L. Richeldi (Rome, Italy), J. Simonetti (Rome, Italy)
| |
Stabilised, synthetic sulforaphane in hospitalized patients with suspected COVID-19 pneumonia: a double-blind, placebo-controlled RCT
H. Abo-Leyah (Dundee, United Kingdom), M. Long (Dundee, United Kingdom), Y. Giam (Dundee, United Kingdom), T. Vadiveloo (Aberdeen, United Kingdom), R. Hull (Sheffield, United Kingdom), H. Keir (Dundee, United Kingdom), T. Pembridge (Dundee, United Kingdom), D. Alferes De Lima (Dundee, United Kingdom), B. New (Dundee, United Kingdom), S. Inglis (Dundee, United Kingdom), A. Gilmour (Dundee, United Kingdom), C. Hughes (Dundee, United Kingdom), L. Delgado (Dundee, United Kingdom), G. Maclennan (Aberdeen, United Kingdom), A. Dinkova-Kostova (Dundee, United Kingdom), J. Chalmers (Dundee, United Kingdom)
| |
Olfactory rehabilitation in non-severe COVID-19 patients: a randomized double-blinded clinical trial
T. SERRANO (CAMPINAS, Brazil), M. Antonio (CAMPINAS, Brazil), L. Giacomin (CAMPINAS, Brazil), J. Ribeiro (CAMPINAS, Brazil), E. Sakano (CAMPINAS, Brazil)
| |
Impact of Dexamethasone Treatment on COVID-19 Pneumonia Mortality
K. Tsitouras (Gerlingen, Germany), A. Ghiani (Gerlingen, Germany), D. Ayubi (Gerlingen, Germany), S. Briese (Gerlingen, Germany), L. Nina (Gerlingen, Germany), M. Hansen (Gerlingen, Germany), S. Allgaeuer (Stuttgart, Germany), M. Torzewski (Stuttgart, Germany), K. Rothfuss (Stuttgart, Germany), L. Gernhold (Gerlingen, Germany), C. Neurohr (Gerlingen, Germany)
| |
Predictors of mortality in tocilizumab treated severe covid-19
K. Pagkratis (Corfu, Greece), S. Chrysikos (Corfu, Greece), E. Antonakis (Corfu, Greece), A. Pandi (Corfu, Greece), C. Kosti (Corfu, Greece), E. Markatis (Corfu, Greece), G. Hillas (Corfu, Greece), A. Digalaki (Corfu, Greece), S. Koukidou (Corfu, Greece), E. Chaini (Corfu, Greece), A. Afthinos (Corfu, Greece), K. Dimakou (Corfu, Greece), I. Papanikolaou (Corfu, Greece)
| |
Pharmacokinetics and pharmacodynamics of imatinib in COVID-19 patients
N. Baalbaki (Amsterdam, Netherlands), J. Aman (Amsterdam, Netherlands), P. Bet (Amsterdam, Netherlands), E. Duijvelaar (Amsterdam, Netherlands), J. Twisk (Amsterdam, Netherlands), C. Longo (Amsterdam, Netherlands), K. Mahmoud (Amsterdam, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), E. Swart (Amsterdam, Netherlands), H. Bogaard (Amsterdam, Netherlands), I. Bartelink (Amsterdam, Netherlands)
| |